Biomarkers to Guide MBC Treatment Decisions: PIK3CA, BRCA1/BRCA2, and PD-L1/PD-1 - Metastatic Breast Cancer Trial Talk

From the Experts

A biomarker is a gene, protein, or molecule produced by the body or tumor in a person with cancer that tells a doctor something about the cancer cells. MBC experts studied biomarkers to develop new recommendations for doctors on how to use biomarker information to carefully make MBC treatment decisions.

This month, we begin a 3-part series that explains the biomarkers in these new recommendations.

People who participated in clinical trials helped contribute to the strong evidence that supports these recommendations. Clinical trial participation continues to be important to gather new information about other biomarkers that do not have strong evidence for recommendations.

Click the links below to read about the new biomarker recommendations, how the PIK3CA, BRCA1/BRCA2, and PD-L1/PD-1 biomarkers help doctors make treatment decisions, and about current clinical trials related to these biomarkers.

Biomarkers for Guiding MBC Treatment
PIK3CA Biomarker
BRCA1/BRCA2 Biomarkers
PD-L1/PD-1 Biomarkers
Clinical Trials Using Biomarkers for Treatment Decision Making

Last Modified on September 26, 2023



for past articles or specific information.